FIGO and IMS Reframe Hormone Therapy for Premature Ovarian Insufficiency
This joint FIGO-IMS position paper reconceptualizes POI and early menopause as chronic endocrine conditions requiring higher-dose, longer-duration hormone replacement rather than symptom-driven menopause management.
📅 Journal publication: Aug 2026(online Aug 18, 2026)·Last updated: Oct 6, 2026
FIGO-IMS joint position paperInternational Federation of Gynecology and ObstetricsInternational Menopause Societypremature ovarian insufficiencyearly menopausehormone therapyestradiolprogestogensNK3R antagonistsWomen's Health
Background Information
Time to rethink hormone therapy for early menopause.
Premature ovarian insufficiency (POI) and early menopause (EM) lead to longer estrogen deficiency, increasing risks of various health issues. The paper advocates for a shift in managing POI/EM as chronic endocrine conditions, emphasizing timely hormone therapy (HT) initiation and long-term care. This position paper suggests reframing HT as essential preventive care for POI/EM, highlighting the need for awareness and equitable access to multidisciplinary care. POI and EM require proactive hormonal management to prevent long-term health issues.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Benedetto C, Khadilkar SS, Nappi RE, Genazzani AR, Frezet F, Cucinella L, Divakar H, Anagnostis P, Panay N
Citation:Benedetto C, Khadilkar SS, Nappi RE, et al. Hormone therapy (HT) in women with premature ovarian insufficiency or early menopause: Time to think of a new paradigm for healthy aging. A joint FIGO and IMS position paper. Climacteric : the journal of the International Menopause Society. 2026;29(4):487-506. doi:10.1080/13697137.2026.2691828